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SUMMARY – Myasthenia gravis and Graves’ disease are two autoimmune diseases with a 
similar mechanism, both having circulating organ autoantibodies and cell speciﬁ c autoantibodies. 
It is not unusual for these diseases to occur together. Th ere is a large body of data proving that 
antithyroid drugs such as methimazole and propylthiouracil have an immunomodulatory eﬀ ect in 
addition to their thyrosuppressant action. Th is case report describes a 34-year-old woman hospitali-
zed for just diagnosed myasthenic crisis (Osserman IV). She had a prior history of hyperthyroidism 
and treatment with methimazole was initiated. However, improvement in thyroid disease led to the 
burst of myasthenia. Th e phenomenon described as worsening of one disease while improving the 
other, the so-called ‘see-saw’ relationship, occurred in this case. Th e question is whether antithyroid 
drugs improve hyperthyroidism while unveiling or worsening myasthenia. Is the ‘see-saw’ relation-
ship actually a therapeutic side eﬀ ect of antithyroid drug? Th e proposed mechanism of methimazole 
action is intracellular: it lowers the level of proliferating cell nuclear antigen (PCNA). PCNA pro-
motes selective apoptosis in some T lymphocyte clones. In this way, CD4+CD25+ regulatory T cells 
might ‘skip’ immune self-tolerance and autoantibodies against acetylcholine receptor may occur. Do 
antithyroid drugs actually create an immune ‘thymic surrounding’?
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Introduction
Th yroid gland is the organ with perhaps most com-
mon autoimmune pathology. Having one autoimmune 
disease in the body increases the chance of developing 
another one1 . Th ere also are syndromes that include 
more autoimmune features connecting thyroid gland 
and myasthenia gravis, e.g., polyglandular syndrome 
type II (Schmidt’s syndrome)2. Schmidt’s syndrome is 
characterized by the presence of two or more autoim-
mune diseases, usually aﬀ ecting thyroid gland, adre-
nal glands and endocrine pancreas. It is not unusual 
that other diseases like myasthenia, hypogonadism, 
pernicious anemia, Parkinson’s disease and celiac dis-
ease occur. Polyglandular syndrome type II is linked 
with HLA DR3 and HLA DR4 locus, inherited in 
the autosomal dominant mode with variable expres-
sivity3. Th ere are a number of reports describing the 
same incidence of myasthenia gravis and thyroid 
disease, with or without polyglandular syndrome, so 
that statistically as many as 5%-10% of patients suf-
fering from myasthenia have some kind of thyroid 
autoimmunity4,5. Th e prevalence of myasthenia gravis 
in Graves’ disease is 0.14%6 . Although there are known 
HLA typing points to the possible HLA DQ3 asso-
ciation in patients with myasthenia and hyperthyroid-
ism, the exact relationship between these two diseases 
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remains unknown7 . Th e mechanism of both diseases 
is autoimmune, with circulating organ autoantibod-
ies and cell speciﬁ c autoantibodies (anti-acetylcholine 
receptor antibody in myasthenia and anti-thyrotropin 
receptor antibody in Graves’ disease). Both diseases 
produce neuromuscular symptoms that sometimes 
resemble each other (weakness and fatigue). Both 
diseases are more common in females and in younger 
patients8. A ‘see-saw’ relationship between Graves’ 
disease and myasthenia gravis has already been docu-
mented, describing worsening of one disease while 
improving the other9,10. It is well known that thyro-
static drugs have both thyrosuppressant action and an 
additional immunomodulatory eﬀ ect. While treating 
hyperthyroidism, microsomal antibodies and thy-
rotropin receptor antibodies decrease independently 
of the thyroid hormone level11,12. Other autoimmune 
events have also been reported while treating patients 
with antithyroid drugs. In some patients, development 
of the insulin autoimmune syndrome was observed13. 
Even agranulocytosis, a well known side eﬀ ect of thy-
rostatic drugs, is by some authors explained by immu-
noreactivity14. Antineutrophil cytoplasmic antibody 
(ANCA)-mediated vasculitis is also associated with 
this therapy15. Finally, psoriasis, a skin disease me-
diated by activated T cells, seems to improve during 
treatment with thyrostatic drugs16. Considering all 
information mentioned above, it should not be taken 
for surprise that some other autoimmune diseases oc-
cur during thyrostatic treatment for Graves’ disease. 
We suggest that the ‘see-saw’ relationship observed in 
myasthenia and Graves’ disease is actually a side ef-
fect of thyrostatic therapy. Th is drug therapy improves 
hyperthyroidism while unveiling or worsening the al-
ready existing myasthenia gravis.
Case Report 
A 34-year-old woman was admitted to the hos-
pital for extreme muscular weakness and cyanosis. 
Blood gas analysis suggested hypoventilation syn-
drome (saturation 55%) that required immediate in-
tubation and mechanical ventilation. Her medical 
history included left optical nerve excision long time 
before, with consequential ptosis of the left superior 
palpebra. She was treated four years for hyperthyroid-
ism due to diﬀ use antibody negative goiter. Th yroid 
gland ultrasonography showed diﬀ usely inhomoge-
neous tissue measuring 8.3x2.8x3.6 cm in the left 
lobe and 8.8x2.9x2.7 cm in the right lobe. Ophthal-
mologic examination revealed thyrotoxic orbitopathy 
and ptosis of the left palpebra. Th e patient had several 
relapses due to non-compliance with her thyrostatic 
drug; she was reluctant to other types of therapy, not 
visiting endocrinologist regularly. Th e last relapse oc-
curred two months before admission, predominantly 
manifesting with cardiologic symptoms, paroxysm 
and atrial ﬂ utter. Her laboratory ﬁ ndings at the time 
of relapse were as follows: TSH 0.1; T3 7.6 nmol/L; 
and T4 400 nmol/L (normal ranges: TSH 0.4-4.2 
mIU/L; T3 1.3-2.5 nmol/L; and T4 70-165 nmol/L); 
free T3 3.6-7.8 pmol/L; and free T4 8-23 pmol/L; 
so methimazole was administered. Atrial ﬂ utter was 
converted to sinus rhythm. Two months later, thyroid 
function improved and so did laboratory ﬁ ndings (T3 
2.1 nmol/L and T4 80 nmol/L). During this period, 
she experienced muscle weakness, fatigability of up-
per and lower extremities, dysphonia, dysphasia, and 
progressive breathlessness. Her symptoms improved 
at rest and deteriorated upon muscular work, dur-
ing conversation in particular. Since neuromuscular 
disease was suspected, a neurologist was consulted 
and Prostigmine test was performed. A positive re-
sult conﬁ rmed myasthenic crisis (grade Osserman IV 
or American Myasthenia Gravis Foundation grade 
V)17, although prior ptosis of the left superior palpe-
bra made the diagnosis somewhat diﬃ  cult. Computer 
tomography (CT) scan showed no thymus, but anti-
AChR antibodies were positive. Th erapeutic regimen 
included three plasmapheresis procedures, glucocor-
ticoid (methylprednisolone) and acetyl cholinesterase 
inhibitor (pyridostigmine). Following plasmapheresis, 
her clinical status rapidly improved. Th e patient was 
improving quickly and was extubated on day 6. Th y-
roid hormone levels dropped (T3 0.6 nmol/L and T4 
19 nmol/L). At that time, methimazole was discontin-
ued. She was discharged from the hospital with oral 
corticoid and pyridostigmine. Further endocrinologist 
evaluation showed no other elements of polyglandular 
syndrome, but levothyroxine substitution was intro-
duced due to the low thyroid hormone levels. Th en, 
laboratory ﬁ ndings showed T3 1.3 nmol/L; free T3 
4.7 pmol/L; T4 78 nmol/L; free T4 9.4 pmol/L; and 
levothyroxine dosage was corrected. Her muscular 
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strength improved even more. Two months later, total 
thyroidectomy was performed while being euthyroid 
(histopathology: Basedow’s goiter), with no diﬃ  cul-
ties in anesthetic procedure. Her postoperative re-
covery was unremarkable, and she was discharged on 
postoperative day 6. Following surgery, myasthenia 
persisted with gradual improvement and she was able 
to perform almost all daily activities. Several months 
after the surgery, she had no muscular symptoms; the 
corticoid and pyridostigmine dosage was tapered and 
eventually discontinued. At the last follow up, her 
neuromuscular status was normal. Th e only medica-
tion she took was 100 mg of levothyroxine.
Antithyroid Drugs and Occurrence of Myasthenia 
Antithyroid drugs were discovered by accident 
about 60 years ago. Hypothyroidism was found as a 
side eﬀ ect during the treatment of heart disease with 
thiocyanate. Th yrostatic drugs, thionamides, contain 
a sulphhydryl group with thiourea part placed in the 
heterocyclic structure. Propylthiouracil (6-propyl-2
-thiouracil) and methimazole (1-methyl-2-mercap-
toimidazole) are frequently used, while carbimazole, 
a methimazole analogue, is used occasionally. Th ion-
amides inhibit thyroid peroxidase, an enzyme that en-
ables iodination of tyrosine residues in thyroglobulin. 
Propylthiouracil inhibits conversion of thyroxin to tri-
iodothyronine both in the gland and peripherally18. 
A number of autoimmune events mentioned above 
are the consequences of immunomodulatory action of 
thyrostatic drugs. In vitro, they might interfere with 
mitogenic activation of lymphocytes. Th ey suppress 
the activation of lymphocytes stimulated by phyto-
hemagglutinin and concanavalin A, and enhance the 
activation of lymphocytes stimulated by pokeweed 
mitogen (PWM)19,20. Th yrostatic drugs increase the 
ratio of T suppressor/cytotoxic cells to T helper cells, 
and increase total number of T-cells in peripheral 
blood21. Antithyroid drugs decrease the IgM and IgG 
production from lymphocytes in peripheral blood, 
stimulated by PWM19. Methimazole has been shown 
to enhance the natural killer cell activity20.  
Another clue could be the ‘nuclear level of ac-
tion’. Propylthiouracil and methimazole lead to a de-
crease in the level of proliferating cell nuclear antigen 
(PCNA)22. PCNA is a protein molecule that regu-
lates cell apoptosis. Th e PCNA gene is induced by 
p53, a tumor-suppressor gene. If there is no PCNA, 
or if its level is low, or if PCNA is non-functional, cell 
apoptosis occurs23. According to this concept, non-
activated lymphocytes have low to none PCNA level, 
whereas stimulated lymphocytes have high PCNA22. 
Anti-PCNAs are also found in some patients suﬀ er-
ing from systemic lupus erythematosus24.
Th e question is whether such changes could pro-
voke an autoimmune event, e.g., myasthenia gravis. 
Th e possible hint could be in one of the most common 
causes of myasthenia, the thymus. All kinds of thymic 
abnormalities are found in nearly 75% of patients with 
myasthenia, so thymus is a good model for investiga-
tion of immune changes in these patients17. Myasthe-
nia gravis is principally caused by anti-acetylcholine 
receptor antibodies produced by B-cells, although it 
seems that T-suppressor cell is the major regulator of 
autoimmune response. T suppressor cell, as its name 
says, suppresses immune response of other cells. Th ere 
are speciﬁ c so-called regulatory T cells (Treg) that are 
derived from thymus, are denoted as CD4+CD25+ 
and are basic for the balance of immune self tolerance. 
Studies with molecular mimicry between microbial 
and self-antigen have proposed that CD4+CD25+ 
regulatory T cells are able to provoke autoimmunity, 
e.g., to raise the threshold of auto-reactive T cell re-
sponse triggering25. 
Myasthenia gravis is a CD4+ T cell-dependent au-
toimmune disease with thymus as the site of origin26. 
In the initial course of myasthenia, thymus is hyper-
plasic with auto-reactive activated CD4+CD25+ T 
cells27. It was shown that thymectomy decreased CD4 
or CD8 T cell concentrations whenever thymopoi-
esis was active before thymectomy28. Th e question 
is whether antithyroid drugs could induce some in-
tracellular changes while inﬂ uencing PCNA, which 
could lead to selective apoptosis in some clones of T 
lymphocytes. In this way, CD4+CD25+ regulatory T 
cells could be able to create a ‘skip’ in the immune 
self tolerance, thus leading to autoantibodies against 
acetylcholine receptor. Are antithyroid drugs actually 
making an immune ‘thymic surrounding’? 
Th ere is another similar report suggesting that 
worsening of myasthenia gravis might be induced by 
methimazole29. In 1991, Kuroda et al. described a 19-
year-old patient with ocular type of myasthenia gravis 
associated with autoimmune hyperthyroidism and 
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thymic hyperplasia. Myasthenia worsened abruptly 
upon initiation of methimazole administration. Lab-
oratory ﬁ ndings showed an increase in serum levels of 
antibodies to thyroid microsome and TSHR and in 
the proliferative response of peripheral blood lympho-
cytes to phytohemagglutinin29.
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Sažetak
MIASTENIČNA KRIZA KAO NUSPOJAVA LIJEČENJA METIMAZOLOM: PRIKAZ SLUČAJA
M. Baretić, S. Balić i G. Gudelj
Miastenija gravis i Gravesova bolest su dvije autoimune bolestI sa sličnim mehanizmom nastanka, u objema se nalaze 
cirkulirajuća antitijela te stanično speciﬁ čna autoantitijela. Pojava navedenih bolesti zajedno nije neuobičajena. Postoji 
mnogo podataka koji pokazuju da antitireoidni lijekovi kao što su metimazol i propiltiouracil uz tireosupresivno djelovanje 
imaju i imunomodulacijski učinak. Opisuje se slučaj 34-godišnje bolesnice koja je hospitalizirana zbog prvi puta dijagno-
sticirane miastenije sa slikom miastenične krize (Osserman IV.). U njenoj ranijoj povijesti bolesti navodila se hipertireoza, 
zbog čega je započeto liječenje metimazolom. Međutim, uz poboljšanje bolesti štitnjače došlo je do pojave miastenije. 
Fenomen “klackalice”, tj. see-saw relationship, je pojava opisana kao poboljšanje jedne bolesti za vrijeme pogoršanja druge. 
Pitanje je poboljšavaju li antitireoidni lijekovi hipertireozu, u isto vrijeme razotkrivajući ili pogoršavajući miasteniju?. Je 
li fenomen “klackalice” zapravo nuspojava tireostatika? Pretpostavljeni učinak metimazola je unutarstanični: on snižava 
razinu nuklearnog antigena stanične proliferacije (PCNA). PCNA potiče selektivnu apoptozu u nekim klonovima T 
limfocita. Na taj bi način CD4+CD25+ regulatorni T limfociti mogli ‘zaobići’ imunu toleranciju prema vlastitom tkivu te 
dovesti do pojave autoantitijela protiv acetilkolinskog receptora. Stvaraju li zapravo doista antitireoidni lijekovi okruženje 
slično onome u timusu?
Ključne riječi: Hipertireoza – komplikacije; Hipertireoza – terapija lijekovima; Miastenija gravis – komplikacije; Miastenija 
gravis – terapija lijekovima; Metimazol – štetni učinci
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